RedHill Biopharma Ltd. (RDHL) stock
RDHLNasdaqPharmaceutical Preparations
$0.35+0.00 (0.00%)
Close on Nov 18, 2026Market cap $1.78MP/E –Yield –
RedHill Biopharma operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
For fiscal 2025 it was -$7.94M. The highest annual figure on record is -$6.48M in fiscal 2024.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$7.94M | – |
| FY2024 | Dec 31, 2024 | -$6.48M | – |
| FY2023 | Dec 31, 2023 | -$9.55M | – |
| FY2022 | Dec 31, 2022 | -$42.84M | – |
| FY2021 | Dec 31, 2021 | -$81.14M | – |
| FY2020 | Dec 31, 2020 | -$63.68M | – |
| FY2019 | Dec 31, 2019 | -$43.20M | – |
| FY2018 | Dec 31, 2018 | -$39.33M | – |
| FY2017 | Dec 31, 2017 | -$51.97M | – |
| FY2016 | Dec 31, 2016 | -$30.54M | – |
| FY2015 | Dec 31, 2015 | -$22.00M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2022 | Jun 30, 2022 | -$9.16M | – |
| Q2 FY2021 | Jun 30, 2021 | -$24.89M | – |
| Q2 FY2020 | Jun 30, 2020 | -$12.50M | – |
| Q2 FY2019 | Jun 30, 2019 | -$12.38M | – |
| Q2 FY2018 | Jun 30, 2018 | -$9.56M | – |
| Q2 FY2017 | Jun 30, 2017 | -$13.54M | – |
See a number that looks wrong?